Hypera (OTCMKTS:HYPMY – Get Rating) and Myovant Sciences (NYSE:MYOV – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.
Risk and Volatility
Hypera has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500.
Get Hypera alerts:Profitability
This table compares Hypera and Myovant Sciences' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hypera | N/A | N/A | N/A |
| Myovant Sciences | -54.03% | N/A | -29.25% |
Valuation & Earnings
This table compares Hypera and Myovant Sciences' revenue, earnings per share (EPS) and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hypera | $793.81 million | 6.73 | $251.25 million | N/A | N/A |
| Myovant Sciences | $230.97 million | 8.23 | -$205.98 million | ($1.76) | -11.26 |
Hypera has higher revenue and earnings than Myovant Sciences.
Insider and Institutional Ownership
0.1% of Hypera shares are owned by institutional investors. Comparatively, 30.6% of Myovant Sciences shares are owned by institutional investors. 1.9% of Myovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and target prices for Hypera and Myovant Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hypera | 0 | 0 | 0 | 0 | N/A |
| Myovant Sciences | 0 | 1 | 1 | 0 | 2.50 |
Myovant Sciences has a consensus target price of $17.67, suggesting a potential downside of 10.86%. Given Myovant Sciences' higher possible upside, analysts clearly believe Myovant Sciences is more favorable than Hypera.
Summary
Myovant Sciences beats Hypera on 6 of the 11 factors compared between the two stocks.
About Hypera
(Get Rating)
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
About Myovant Sciences
(Get Rating)
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.